A recent study found that a significant number of patients with multiple myeloma harbor potentially actionable oncogenic molecular alterations, prompting a need for novel precision medicine approaches. READ MORE

Author Insights

Recent research has uncovered a non-inferior, cost-effective alternative to standard therapy for autologous stem cell mobilization in multiple myeloma. The study’s author discusses his findings.

READ MORE

News

A recent study found that a significant number of patients with multiple myeloma harbor potentially actionable oncogenic molecular alterations, prompting a need for novel precision medicine approaches.

READ MORE

A recent study found that continued therapy with a combination regimen until disease progression improves outcomes in patients with newly diagnosed multiple myeloma who are not eligible for ASCT.

READ MORE

Results of a recent study showed that the prognostic implications of patient-specific and tumor biological features vary significantly across age-groups of patients with multiple myeloma.

READ MORE

A recent study confirmed the most cost-effective treatment option in heavily pretreated patients with relapsed or refractory multiple myeloma.

READ MORE

Research in Review

The Levine Cancer Institute of the Carolinas HealthCare System has had a large impact on hematopoietic cell transplant outcomes.

READ MORE

Resources

The National Comprehensive Cancer Network has implemented categories of preference for recommendations within their clinical practice guidelines in oncology.

READ MORE

Special Reports

The final section of the special report speculates on the future treatment landscape for relapsed or refractory multiple myeloma.

READ MORE

The fourth section of the report reviews the economic implications of a multiple myeloma diagnosis.

READ MORE

The next section of the report analyzes how clinical pathways support evidence-based treatment decision making for multiple myeloma.

READ MORE

The second section of the report explores the challenges of treatment resistance and relapse in multiple myeloma.

READ MORE